DOCSLIB.ORG

Associations Between Canine Male Reproductive Parameters And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Associations Between Canine Male Reproductive Parameters And Associations between Canine Male Reproductive Parameters and Serum Vitamin D and Prolactin Concentrations by Adria Julianne Kukk A Thesis presented to The University of Guelph In partial fulfillment of requirements for the degree of Doctor of Veterinary Science in Population Medicine Guelph, Ontario, Canada ¤ Adria Julianne Kukk, December, 2011 ABSTRACT ASSOCIATIONS BETWEEN CANINE MALE REPRODUCTIVE PARAMETERS AND SERUM VITAMIN D AND PROLACTIN CONCENTRATIONS Adria Julianne Kukk Advisor: University of Guelph, 2011 Professor C.J. Gartley Maintaining reproductive health and diagnosing and treating conditions of infertility in stud dogs is important in canine theriogenology. However, there is still a great deal to be learned about reproductive physiology and factors that affect reproductive organs and semen quality in dogs. This thesis is an investigation of two factors in the male dog; serum 25-hydroxy Vitamin D (25OHVD) and prolactin (PRL) concentrations, and their possible associations with benign prostatic hyperplasia (BPH), prostate volume and/or sperm morphology and motility characteristics. 28 (Vitamin D Study) and 29 (28 plus one for the Prolactin study) client dogs of various breeds from the Ontario Veterinary College and Graham Animal Hospital in Southwestern Ontario, Canada were enrolled in the study from March to December 2009. Of these dogs 22 were successfully collected for semen. BPH was diagnosed using prostate volume measured by ultrasound, as well as clinical signs including blood in the ejaculate. Semen analysis was performed using manual microscopic techniques for morphology and computer assisted sperm analysis equipment for motility. In the vitamin D study, no associations were found between BPH and serum 25OHVD concentrations. In contrast, several sperm motility (motility, progressive motility, beat cross frequency (BCF), distance average path (DAP), curvilinear distance (DCL), linear distance (DSL), average path velocity (VAP), curvilinear velocity (VCL) and straight line velocity (VSL), amplitude lateral head displacement (ALH) and average orientation change (AOC)) and morphology characteristics (percentage normal sperm, head defects and detached heads) had desirable outcomes with 25OHVD concentrations between 120-180 nmol/l. Using bivariable analysis, positive associations were observed with 25OHVD and some semen quality characteristics from 4 to 8 years of age (motility, progressive motility, BCF, DCL, VCL, ALH, AOC) and at transformed prostate volumes smaller than or equal to 4.5 (motility, progressive motility, DCL, VCL, and normal morphology) while negative associations of these semen parameters were found at ages greater than 8 years and transformed prostate volumes greater than or equal to 5.5. Head defects were negatively associated with 25OHVD. Vitamin D may have an impact on spermatogenesis and normal sperm physiology that warrants further research. The prolactin study showed no statistically significant associations between serum PRL and BPH and serum PRL and sperm motility characteristics. However, two sperm morphology characteristics (percentage proximal droplets and percentage midpiece defects) had significant negative associations with PRL concentrations. Age interaction with PRL was also a factor in the percentage of midpiece defects with desirable outcomes associated at 4 years of age compared with older ages. Overall, undesirable outcomes occurred at PRL concentrations less than 2.5 ng/ml. In conclusion, both 25OHVD and PRL may have important roles in spermatogenesis and normal sperm physiology in the dog. ACKNOWLEDGEMENTS The past few years have been an exciting and important part of my life. I would not have been able to complete this great undertaking without the support and knowledge of a great many people. First I would like to thank my advisor Dr. Cathy Gartley for her wealth of knowledge in the field of theriogenology, for her mentorship, her kindness and lastly, for her sense of humour to make me laugh even on the greyest of days. Also, I would like to thank members of my advisory committee: Drs. Tracey Chenier, Andria Jones, Stephanie Nykamp and Heather Chalmers for their patience and expertise in guiding me through my research and for their critical advice in pushing me to create a body of work I can be proud of. For his statistical expertise, I am grateful to William Sears whose help was invaluable in the analysis of my data. For their friendship, support and encouragement during my D.V.Sc. programme I would like to thank Drs. Rasa Levstein and Cyril Stephen, our veterinary technicians Jim Rahn and Karen DiCaro, as well as my fellow graduate students Drs. Mariana Diel De Amorim and Leslie Gonzalez. I would also like to thank Dr. Walter Johnson for his encouragement and for sharing his knowledge of bovine theriogenology. A special thank-you to Sally, Linda, Julie and Karla in the Population Medicine office, and Mary Elliot for helping me with the bureaucratic aspects of graduate studies and for making my life that much easier. To Dr. Carol Graham, all the staff at Graham Animal Hospital, and to all our clients who agreed to enroll their dogs in this study, I extend a warm v appreciation for their participation. Without them there wouldn’t have been any data to analyse. I wish to also thank the Pet Trust for providing the funding to make this study possible. Lastly, I would like to thank two very special people in my life, my mother Eva and my husband Anthony (Toncsi) for the much needed emotional support during my graduate programme. Their patience and unending belief in me gave me the strength I needed to achieve my goals. vi DECLARATION OF WORK PERFORMED I declare that with the exception of the items listed below, all work presented in this thesis was performed by me. The Animal Health Laboratory, University of Guelph, performed urinalysis and culture and sensitivities for urine, prostatic fluid and semen. The Endocrinology Division of the Diagnostic Center of Population and Animal Health, Michigan State University, performed the radioimmunoassay for Vitamin D analysis. The New Animal Science Laboratory, Washington State University, performed the enzyme-linked immunosorbent Assay for Prolactin analysis. vii TABLE OF CONTENTS CHAPTER ONE ………………………………………………………………… 1 INTRODUCTION, RESEARCH OBJECTIVES AND LITERATURE REVIEW …………………………………………................................... 1 1. INTRODUCTION …………………………………………………….. 1 2. RESEARCH OBJECTIVES..………………………………………… 3 3. LITERATURE REVIEW.……………………………………………… 4 3.1 PHYSIOLOGY OF CANINE SPERMATOGENESIS AND METHODS OF SEMEN ANALYSIS………………………… 4 3.1.1 Reproductive Physiology of the Testes and the Role of Hormones and Local Factors In Male Reproduction….. 4 3.1.2 Spermatogenesis ………………………………………. 13 3.1.3 Factors Affecting Semen Quality.…………………… 16 3.1.4 Methods of Semen Evaluation……………………… 17 3.2 THE CANINE PROSTATE GLAND ……………………….. 31 3.2.1 Anatomy and Physiology of the Prostate Gland ……... 31 3.2.2 Pathophysiology of Benign Prostatic Hyperplasia…….. 33 3.2.3 Conventional Treatment of Benign Prostatic Hyperplasia ……………………………………………….. 39 3.2.4 Ultrasonography of the Prostate.……………………….. 42 3.3 VITAMIN D AND ITS ROLE IN MALE REPRODUCTION.. 44 3.3.1 Vitamin D Metabolism ………………………………… 45 3.3.2 Vitamin D and the Prostate …………………………… 49 3.3.3 Role of Vitamin D in Sperm Production ……………… 54 3.4 PROLACTIN AND ITS ROLE IN MALE REPRODUCTION.. 56 3.4.1 Prolactin and Ovarian Physiology.……………………. 56 3.4.2 Prolactin and Male Physiology.………………………. 58 3.4.2.1 Prolactin and the Prostate.…………………………. 58 3.4.2.2 Prolactin, Male Fertility and Semen Quality ……… 60 viii References ………………………………………………………… 67 CHAPTER TWO …………………………………………………………… 81 VITAMIN D, BENIGN PROSTATIC HYPERPLASIA, PROSTATE VOLUME AND SEMEN PARAMETERS IN THE DOG………… 81 Abstract.……………………………………………………………... 81 1. Introduction……………………………………………………….. 82 2. Materials and Methods.………………………………………….. 84 3. Results.……………………………………………………………. 92 4. Discussion and Conclusions.…………………………………… 98 References ………………………………………………………….. 143 CHAPTER THREE.…………………………………………………………… 147 PROLACTIN, BENIGN PROSTATIC HYPERPLASIA, PROSTATE VOLUME AND SEMEN PARAMETERS IN THE DOG.. 147 Abstract.………………………………………………………………... 147 1. Introduction …………………………………………………………. 148 2. Materials and Methods ……………………………………………. 151 3. Results ……………………………………………………………… 155 4. Discussion and Conclusions ……………………………………… 157 References.…………………………………………………………….. 178 CHAPTER FOUR …………………………………………………………….. 180 SUMMARY AND CONCLUSIONS ………………………………… 180 References……………………………………………………………. 184 APPENDICES ……………………………………………………………….. 185 ix LIST OF TABLES Table 1.1 Selected Physical and Chemical Analyses of Prostatic Fluid in Dogs with Healthy Prostates.…………………………………………… 33 Table 1.2 Genes influenced by Vitamin D receptor ligands and their effects 48 Table 1.3 Prolactin values in Dogs (ELISA) ……………………………………65 Table 2.1 Technical Parameters for SpermVision™ CASA …………………111 Table 2.2 Classification scheme for determination of the presence of BPH by ultrasonography in 29 dogs, March-December 2009, Ontario, Canada ………………………………………………………….112 Table 2.3 Characteristics of the study population of 28 dogs, in Ontario, Canada, March-December 2009.……………………………………….113 Table 2.4 Characteristics of the study population of 22 dogs from whom semen was collected in Ontario, Canada March-December 2009…………...114 Table 2.5 Breed, Vitamin D concentration, age and fertility data on 22 dogs from whom semen was collected in Ontario, Canada, 2009…………115 Table 2.6 Mean serum Vitamin
Load more

Recommended publications
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • The Effects of Osaterone Acetate on Clinical Signs and Prostate Volume in Dogs with Benign Prostatic Hyperplasia
    Polish Journal of Veterinary Sciences Vol. 21, No. 4 (2018), 797–802 DOI 10.24425/pjvs.2018.125601 Original article The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia P. Socha, S. Zduńczyk, D. Tobolski, T. Janowski Department of Animal Reproduction with Clinic, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn, Poland Abstract A clinical trial was performed to evaluate the therapeutic efficacy of osaterone acetate (OSA) in the treatment of benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate (Ypozane, Virbac) was administered orally at a dose of 0.25 mg/kg body weight once a day for seven days to 23 dogs with BPH. During the 28-day trial, the dogs were monitored five times for their clinical signs and prostate volume. The OSA treatment promoted rapid reduction of clinical scores to 73.2% on day 7 and to 5.9% on day 28 (p<0.05). Osaterone acetate induced the complete clinical remission in approximately 83.0% of the dogs on day 28. The prostate volume regressed to 64.3% of the pretreatment volume after two weeks of the treatment (p<0.05) and to 54.7% at the end of the trial (p<0.05). In conclusion, OSA quickly reduced clinical signs and volume of the prostate glands in dogs with BPH. Key words: dogs, benign prostatic hyperplasia, osaterone acetate, prostate volume Introduction hyperplasia and subsequently transforms to cystic hyperplasia with the formation of multiple small cysts Benign prostatic hyperplasia (BPH) is the most within the prostatic parenchyma.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • Reproductive Endocrinology of the Dog
    Reproductive endocrinology of the dog Effects of medical and surgical intervention Jeffrey de Gier 2011 Cover: Anjolieke Dertien, Multimedia; photos: Jeffrey de Gier Lay-out: Nicole Nijhuis, Gildeprint Drukkerijen, Enschede Printing: Gildeprint Drukkerijen, Enschede De Gier, J., Reproductive endocrinology of the dog, effects of medical and surgical intervention, PhD thesis, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands Copyright © 2011 J. de Gier, Utrecht, The Netherlands ISBN: 978-90-393-5687-6 Correspondence and requests for reprints: [email protected] Reproductive endocrinology of the dog Effects of medical and surgical intervention Endocrinologie van de voortplanting van de hond Effecten van medicamenteus en chirurgisch ingrijpen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 20 december 2011 des middags te 12.45 uur door Jeffrey de Gier geboren op 14 mei 1973 te ’s-Gravenhage Promotor: Prof.dr. J. Rothuizen Co-promotoren: Dr. H.S. Kooistra Dr. A.C. Schaefers-Okkens Publication of this thesis was made possible by the generous financial support of: AUV Dierenartsencoöperatie Boehringer Ingelheim B.V. Dechra Veterinary Products B.V. J.E. Jurriaanse Stichting Merial B.V. MSD Animal Health Novartis Consumer Health B.V. Royal Canin Nederland B.V. Virbac Nederland B.V. Voor mijn ouders
    [Show full text]
  • Hexachlorophenum Hexaminolaevulinas Hydrochloridum
    29 Hexachlorophenum Heksaklorofeeni Hexaklorofen Hexachlorophene Hexaminolaevulinas Heksaminolevulinaattihyd- Hexaminolevulinathydro- Hexaminolevulinate hyd- hydrochloridum rokloridi klorid rochloride Hexapropymatum Heksapropymaatti Hexapropymat Hexapropymate Hexobarbitalum Heksobarbitaali Hexobarbital Hexobarbital Hexocyclium Heksosyklium Hexocyklium Hexocyclium Hexoprenalinum Heksoprenaliini Hexoprenalin Hexoprenaline Hexylnicotinatum Heksyylinikotinaatti Hexylnikotinat Hexyl nicotinate Hexylresorcinolum Heksyyliresorsinoli Hexyh-esorcinol Hexylresorcinol Hirudinum Hirudiini Hirudin Hirudin Histamini Histamiinidihydrokloridi Histamindihydroklorid Histamine dihydrochloride dihydrochloridum Histaminum Histamiini Histamin Histamine Histapyrrodinum Histapyrrodiini Histapyrrodin Histapyrrodine Hisb-elinum Histreliini Histrelin Histrelin Homatropini Homati'opiinimetyyli- Homatropinmetylbromid Homatropine methylbromidum bromidi methylbromide Homatropinum Homatropiini Homatropin Homatropine Hormonum parathyroidum Paratyroidihormoni Parathormon Parathyroid hormone (rdna) (rdna) Hyaluronidasum Hyaluronidaasi Hyaluronidas Hyaluronidase Hydralazinum Hydralatsiini Hydralazin Hydralazine Hydrochlorothiazidum Hydroklooritiatsidi Hydroklortiazid Hydrochlorothiazide Hydrocodonum Hydrokodoni Hydrokodon Hydrocodone Hydrocortisonum Hydrokortisoni Hydrokortison Hydrocortisone Hydroflumethiazidum Hydroflumetiatsidi Hydroflumetiazid Hydroflumethiazide Hydromorphonum Hydromorfoni Hydromorfon Hydromorphone Hydrotalcitum Hydrotalsiitti Hydrotalcit Hydrotalcite
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Benign Prostate Hyperplasia
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk BENIGN PROSTATE HYPERPLASIA Author : Henry L’Eplattenier Categories : Vets Date : April 4, 2011 Henry L’Eplattenier considers this common condition in older dogs and discusses its symptoms and treatment THE prostate is the only major accessory sex gland in the dog. It is a bilobed structure that completely encircles the proximal portion of the urethra. In young animals, the prostate lies entirely within the pelvic cavity, but with sexual maturity it increases in size and assumes an abdominal position. Histologically, the prostate has an epithelial and a stromal component. The epithelial cells form tubuloalveoli that drain into the urethra. The prostate is surrounded by a capsule containing smooth muscle fibres that extend into the organ, dividing the alveolar tissue into dis tinct lobules. Blood supply to the prostate is supplied by the prostatic artery, which arises from the pudendal or umbilical artery. Anastomoses can be found between the prostatic vessels and the urethral artery, and the cranial and caudal rectal artery. Venous blood returns via the prostatic vein to the internal iliac vein. Lymph drains into the iliac lymph nodes. Sympathetic innervation is provided by the hypogastric nerve, which stimulates the active secretory process and expulsion of secretions by smooth muscle contractions. Parasympathetic innervation with fibres from the pelvic nerve also contributes to smooth muscle contraction1. 1 / 5 Fluid secreted by the prostate forms more than 90 per cent of the total volume of the ejaculate2 and is expulsed in the first and third fractions of the ejaculate.
    [Show full text]
  • Audition Publique « Auteurs De Violences Sexuelles : Prévention, Évaluation, Prise En Charge »
    Audition publique « Auteurs de violences sexuelles : prévention, évaluation, prise en charge » Rapports des experts et du groupe bibliographique Tome 3 : Évaluation Préface : Mathieu LACAMBRE, Sabine MOUCHET-MAGES Auteurs : François ARNAUD, Roland COUTANCEAU, Julien DA COSTA, Emmanuelle DUSACQ, Bruno GRAVIER, Ivan GUITZ, Hanin HEDJAM, Pierre LAMOTHE, Cédric LE BODIC, Nora LETTO, Frédéric MEUNIER, Valérie MOULIN, Thierry PHAM, Pierre ROUVIERE Suivi de « Synthèse du rapport de la commission d’audition. 35 propositions concrètes pour lutter efficacement contre les violences sexuelles » Edition collector à l’occasion du 10ème Congrès International Francophone sur l’Agression Sexuelle (CIFAS, Montpellier, 2019) ISBN : 978-2-491142-02-5 © FFCRIAVS - 2019 Audition publique « Auteurs de violences sexuelles : prévention, évaluation, prise en charge » Paris, juin 2018 AUDITION Publique «AUTEURS DE VIOLENCES SEXUELLES : PRÉVENTION, ÉVALUATION, PRISE EN CHARGE» Préface Dans le champ des violences sexuelles, nous disposons en France d’un héritage clinique, théorique et conceptuel particulièrement riche ainsi que de dispositifs législatifs inédits (injonction de soins, contrainte pénale…) mais aussi institution- nels permettant une articulation étroite entre la Santé et la Justice autour du pa- tient-condamné. Ainsi, des équipes pluriprofessionnelles originales ont vu le jour à partir de 20061 au sein de Centres Ressources pour les intervenants auprès d’Auteurs de Violences Sexuelles (CRIAVS). Près de 200 professionnels de tout horizon (secré- taire, documentaliste, juriste, sociologue, criminologue, psychologue, éducateur, assistant de recherche clinique, psychiatre, sexologue…) se sont réunis dans chaque région pour incarner les CRIAVS et porter haut nos missions : la prévention, la forma- tion, la documentation, l’information, le soutien aux équipes de terrain, la recherche et l’animation des réseaux Santé-Justice.
    [Show full text]
  • Canine Prostate Disease
    Canine Prostate Disease Bruce W. Christensen, DVM, MS KEYWORDS Prostate Benign prostatic hyperplasia (BPH) Prostatitis Prostatic neoplasia Canine prostate-specific arginine esterase (CPSE) KEY POINTS All intact, male dogs eventually develop benign prostatic hyperplasia and a subset will develop clinical signs associated with subfertility, discomfort, or infection. Any male dog may develop neoplasia associated with the prostate, with a higher propor- tion of neutered males being affected. Ultrasound imaging and prostatic tissue cytology remain the most reliable diagnostic tests for canine prostate disease, but canine prostate-specific arginine esterase shows value as a supporting diagnostic test. Older recommendations to treat prostatitis for 4 to 8 weeks with appropriate antibiotics have been updated to now recommend a truncated 4-week treatment regime for acute cases. Medical treatments for benign prostatic hyperplasia have variable effects on prostate size and function, and may affect androgen production. Video content accompanies this article at http://www.vetsmall.theclinics.com/. INTRODUCTION The prostate is the only accessory sex organ in dogs. Diseases of the canine prostate are relatively common. The canine prostate is constantly developing and growing un- der androgenic influence throughout the life of the intact male dog. This androgenic influence seems to have a protective effect in the case of neoplastic disease,1–3 but the increase in size under androgens also predisposes the canine prostate to infection and cystic disease.4–6 The consequences of these diseases range from mild discom- fort to varying effects on semen quality to very painful or life-threatening illness. An evolving understanding of the way the canine prostate functions has led to expanded diagnostic options and recent changes in treatment recommendations for some of these conditions.
    [Show full text]
  • WO 2020/0951S3 A1 14 May 2020 (14.05.2020) I 4 P Cl I P C T
    (12) INTERNATIONAL APPLICATION PI;BLISHED I. NDER THE PATENT COOPERATION TREATY (PCT) (19) World intellectual Propertv Organraation llIIlIIlllIlIlllIlIllIllIllIIIIIIIIIIIIIIIIIIIIIIllIlIlIlIllIlllIIllIlIIllllIIIIIIIIIIIIIIIIIII International Bureau (10) International Publication Number (43) International Publication Date WO 2020/0951S3 A1 14 May 2020 (14.05.2020) I 4 P Cl I P C T (51) International Patent Classification: MC. MK, MT. M., NO, PL, PT, RO, RS. SE. SI. SK. SM, A6JK3J/4166 (2006.01) A6/K&/5/t)6 (200G 01) TR). OAPI (BF, BJ, CF, CG, CI. CYI. GA, GN, GQ. GW. AGJK39/00(2006 01) C07K/6/28 (2006 01) KM,:vIL. MR, NE. SN, TD, TG) A6JP35/00(200G 01) AGJK38/68 (2019 Ol) Published: (21) International Application tiumber: »iili nrternatinrral seair 6 repurt 14rt 2113&i PCT/IB2019/059459 m Alar/ and &ilnte, the mternat»rrral app/icramn as fihrl (22) International Filing Date: crmiamerl en/«i rrr grevscale a&irl is rivrnhihiefur d«ii nlrrarl 04 November 2019 (04,11.2019) /rum P) TES"/;ST'OPE (25) Filing Langurrge: Enghsh (26) Public&stion Language: Enghsh (30) Priority Data: (&2/755.944 05 Not en&ber 2018105.11 20)8) US (i2/882.424 02 Auknrst 2019 (02 08.2019) US (71) Applicants: PFIZER INC. [US/L S], 233 East 42nd Street. Neve York. Ncw York 10017 (US). MERCK PATENT GMBH [DE/DE], Frankfurter Strasse 250, G4293 Dmm- stadi (DE) NEKTAR THERAPEUTICS [US/US]. 435 Nlission Ba) Boulmard South. Suite 100. San Francis- co, California 94158 (US). ASTELLAS PHARMA INC. f JP/JP], 2-5-1. Nihonbashi-Honcho, Chuo-Ku, Tokv o (JP) (72) Inventors: BOSHOFF, Christoffel Hendrik; c/o PFIZER INC, 235 East 42nd Street Neu York.
    [Show full text]
  • Leitlinienreport S3-Leitlinie Prostatakarzinom | Version 5.0 | April 2018 3
    1 1 1 1 Leitlinienreport Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschie- denen Stadien des Prostatakarzinoms Version 5.0 – April 2018 AWMF-Registernummer: 043/022OL © Leitlinienprogramm Onkologie | Leitlinienreport zur S3-Leitlinie Prostatakarzinom | für Version 2.2 Konsulta- tionsfassung, 2. Aktualisierung 2014 2 Inhaltsverzeichnis 1. Informationen zum Leitlinienreport ................................................................. 6 1.1. Autoren des Leitlinienreports ................................................................................................... 6 1.2. Herausgeber ............................................................................................................................ 6 1.3. Federführende Fachgesellschaft ............................................................................................... 6 1.4. Finanzierung der Leitlinie ........................................................................................................ 6 1.5. Kontakt .................................................................................................................................... 6 1.6. Zitierweise des Leitlinienreports .............................................................................................. 7 1.7. Weitere Dokumente zur Leitlinie .............................................................................................. 7 1.8. Abkürzungsverzeichnis ...........................................................................................................
    [Show full text]
  • Aktualne Metody Farmakologicznego Leczenia Łagodnego Przerostu Prostaty U Psów
    Med. Weter. 2015, 71 (6), 335-340 335 Artykuł przeglądowy Review Aktualne metody farmakologicznego leczenia łagodnego przerostu prostaty u psów JOANNA PASIKOWSKA, WOJCIECH NIŻAŃSKI Katedra Rozrodu z Kliniką Zwierząt Gospodarskich, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy we Wrocławiu, pl. Grunwaldzki 49, 50-366 Wrocław Otrzymano 07.07.2014 Zaakceptowano 21.07.2014 Pasikowska J., Niżański W. Methods of pharmacological treatment of benign prostatic hyperplasia in dogs: An update Summary Benign prostatic hyperplasia (BPH) is the most common disease of the prostate in dogs. It can be treated by surgical or pharmacological methods. Surgical methods are used in non-breeder males or males with pathological changes in the testis. Pharmacological treatment is an alternative for breeder males and old animals with associated diseases. Substances that can be used for medical treatment are GnRH analogues, GnRH antagonists, estrogens, progestogens, antiandrogens, inhibitors of 5α-reductase, antiestrogens, and VDR agonists. This paper presents short characteristics of pharmacological substances that we have used in BPH treatment. Keywords: benign prostatic hyperplasia, dogs, GnRH analogues, GnRH antagonists, antiandrogens Łagodny przerost prostaty (BPH – benign prostatic Najczęstsze objawy towarzyszące BPH to okre- hyperplasia) to najczęstsza choroba dotycząca gruczołu sowe wypływy z cewki moczowej, makroskopowe krokowego u psów. krwawienia podczas oddawania moczu oraz zmiany BPH stwierdza się u 16% psów powyżej drugiego w ejakulacie (krew w nasieniu i zwiększona ilość III roku życia, u 80% psów powyżej 5. roku życia i prak- frakcji nasienia) (20, 35). tycznie u 100% pacjentów powyżej 8. roku życia. Stosunkowo często BPH towarzyszą także problemy BPH diagnozowane jest u psów wszystkich ras oraz z oddawaniem kału – zaparcia, częste i bolesne parcia, mieszańców (14).
    [Show full text]